NICE aims to cut funding for Amgen lung cancer drug Lumykras
Amgen's Lumykras will no longer be funded by the Cancer Drugs Fund for KRAS-mutated lung cancer, says NHS reimbursement authority NICE.
AZ, Ionis hit by unexpected Wainua trial failure
Prospects for AstraZeneca and Ionis' Wainua have been severely dented by a failed trial in ATTR cardiomyopathy, weighing on the shares of both firms.
UK first in Europe to clear Boehringer's IPF drug Jascayd
Boehringer Ingelheim has won the first European approval for its new idiopathic pulmonary fibrosis (IPF) therapy, Jascayd, in the UK.
Aureka offers open-source AI module for drug discovery
Many AIs used in drug discovery are provided by big tech companies at a cost, but a small US and China-based techbio is taking a different tack.
AZ pays $200m upfront for Sino Bio COPD drug
AstraZeneca has licensed a drug candidate for COPD from China's Sino Bio, which could compete with MSD's Ohtuvayre, in a deal valued at up to $2.1bn.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
The Evolution Summit Announces September 2026 Program for Cl...
Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA.
Register Now for AAPS PharmSci 360!
Learn from pharmaceutical scientists involved at every stage of the drug development pipeline at PharmSci 360.
16th World Clinical Biomarkers & CDx Summit
The globe’s longest-standing, industry-dedicated forum for precision medicine is back.
Inizio Launches Intelligent Congress to Turn Event Investmen...
Inizio, the leading global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress
17th World ADC San Diego | October 12-15, 2026
The World’s Premier Forum to Advance Differentiated ADCs to Redefine Early-Line Oncology Patient Outcomes